NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ) announced yesterday results for its fourth-quarter and full year 2024. The company reported 2024 fourth-quarter sales growth of 5.3 percent to $22.5 billion with operational growth of 6.7 percent and adjusted operational growth of 5.7 percent. Full-year 2024 sales growth was reported at 4.3 percent to $88.8 billion with operational growth of 5.9 percent and adjusted operational growth of 5.4 percent. Vision sales within the MedTech segment grew 7.9 percent in the fourth quarter of 2024 and 1.5 percent for full-year 2024.

Worldwide fourth-quarter sales growth of 5.3 percent was led by 10 percent growth in the U.S. Full-year 2024 worldwide growth of 4.3 percent was also led by 8.3 percent growth in the U.S.

Vision sales within the company’s MedTech segment grew 7.9 percent in the fourth quarter of 2024, with contact lens growth of 6 percent driven by trade inventory dynamics, price actions, continued strong performance of the Acuvue Oasys 1-Day family (including the recent launch of Oasys MAX 1-Day), and lapping of prior year impacts from Russia sanctions.

On the surgical side, the company noted that growth was driven by the continued strength of recent innovation (TECNIS PureSee and TECNIS Eyhance IOLs) and commercial execution, partially offset by competitive pressures in the U.S.

For full-year 2024, vision sales grew 1.5 percent, with contact lens sales growth of 3.6 percent, part of the MedTech segment’s 4.8 percent worldwide growth to $31.9 billion.

“We are encouraged by the improvements in vision, another core business. As you know, we had a slower start to 2024 but we saw that improve throughout the year, culminating in operational growth rate in the fourth quarter of 9.1 percent,” Joaquin Duato, chairman and chief executive officer, Johnson & Johnson, said during yesterday’s conference call.

For full-year 2024, MedTech worldwide operational sales grew 6.2 percent, with net acquisitions and divestitures positively impacting growth by 1.5 percent. Innovative Medicine worldwide operational sales, excluding the COVID-19 vaccine, grew 7.5 percent.

"2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Duato. “As a health care company, with a disease-centric approach, we are improving the standard of care in a broad range of diseases with high unmet need, including multiple myeloma, lung cancer, inflammatory bowel disease and heart failure. With our strong financial foundation, differentiated portfolio and robust pipeline, we are well positioned to sustain the high pace of growth and innovation that is the hallmark of Johnson & Johnson.”

Johnson & Johnson said it expects 2025 sales in the range of $90.9 billion to $91.7 billion. The company’s guidance for 2025 forecasts operational sales growth in the range of 2.5 percent to 3.5 percent.